The Cross-Border Biotech Blog

Biotechnology, Health and Business in Canada, the United States and Worldwide

Tag Archives: Ontario Bioscience Industry Organization

Biotech in the Provinces: OBEST Launches Regional Meetings in Ontario; Western Canada Innovation Agreement to Provide Seed Funding

The Ontario Bioscience Economic Strategy Team (OBEST)* is holding regional cluster meetings starting today that will be chaired by bioscience CEOs from across the province. OBEST launched its evergreen strategy to sustain and grow the province’s health-science industry last week with a meeting of the OBEST advisory committee, which is chaired by Dr. Daniel Billen from Amgen Canada, and includes C-level representatives from business, patient groups, government, academia, ag-biotech and Ontario’s biotech companies.

Innovative ideas are being sought from everyone with a stake in the industry via the regional cluster meetings, which will inform the Advisory Committee’s work.

Meanwhile, out West, the Centre for Drug Research and Development, together with the Provinces of British Columbia and Alberta, and Johnson & Johnson Corporate Office of Science and Technologywill administer a fund supporting innovative health research programs, called the Western Canada Innovation Agreement.  The seed funding will enable early-stage discoveries to achieve commercialization in the life sciences sector.  For more information, visit www.jnjcosat.com/cosat.

* OBEST is an initiative of OBIO, where I am the corporate secretary.

OBIO Panel Presents OETF and BIP Information

The Ontario Bioscience Industry Organization (OBIO) and the Ministry of Research and Innovation (MRI) co-hosted an event a few days ago entitled: “Funding Opportunities in 2009-2010 for Bioscience Companies: What CEO’s Need to Know About Ontario’s ETF and BIP Programs.”

The speakers were:

  • Chair: Kevin French, Senior Act. Manager, RBC;
  • Industry:
    • Rocky Ganske (President & CEO, Axela),
    • Peter Pekos (President & CEO, Dalton Pharmaceuticals),
    • Tom Wellner (President & CEO, Therapure Biopharma);
  • Investors:
    • Rob Koturbash (Managing Director, Maple Leaf Angels)
    • Steve Ottaway (Managing Director, GMP Securities),
    • Peter van der Velden (CEO, Lumira Capital);
  • Government:
    • John Marshall (Director, MRI, responsible for OETF)
    • Ryan Lock (Acting Director, MRI, responsible for BIP)

Lots of great information on funding opportunities, and luckily, the whole thing is archived (here) online.  To access the presentation, enter “OBIO” when prompted.

Follow

Get every new post delivered to your Inbox.

Join 129 other followers